Hemophilia in Children: Diagnosis and Management

When a child scrapes their knee or gets a small cut, most parents expect the bleeding to stop within minutes. But for children with hemophilia, even minor injuries can lead to prolonged bleeding that refuses to stop on its own. Hemophilia is a rare genetic disorder that affects the blood’s ability to clot properly, and while it presents lifelong challenges, early diagnosis and proper management can help children lead active, fulfilling lives.

What is hemophilia? 🔗

Hemophilia is an inherited bleeding disorder where blood does not clot properly due to a deficiency in specific clotting factors. Blood contains many proteins called clotting factors that work together to stop bleeding when an injury occurs. Children with hemophilia have low levels of either factor VIII or factor IX, which are essential proteins needed to form blood clots.

There are two main types of hemophilia. Hemophilia A, also known as classic hemophilia, results from a deficiency of clotting factor VIII. This is the most common type, accounting for about 80-85% of all hemophilia cases. Hemophilia B, sometimes called Christmas disease, occurs due to a deficiency of clotting factor IX. Both types share similar symptoms, though hemophilia A is approximately three to four times more common than hemophilia B.

The genetics behind hemophilia 🔗

Hemophilia is caused by mutations in genes located on the X chromosome. Since males have one X and one Y chromosome (XY), while females have two X chromosomes (XX), the inheritance pattern primarily affects boys. A male who inherits an X chromosome carrying the hemophilia gene will develop the condition. Girls who inherit one affected X chromosome typically become carriers but may sometimes experience mild symptoms themselves.

Interestingly, about one-third of hemophilia cases occur in families with no prior history of the disorder. These cases result from spontaneous genetic mutations, meaning parents may have no warning that their child could be affected.

Understanding severity levels 🔗

The severity of hemophilia depends on the amount of clotting factor present in the blood. This classification is crucial because it determines the frequency of bleeding episodes and guides treatment decisions.

Severe hemophilia occurs when clotting factor activity is less than 1% of normal. Children with severe hemophilia often experience spontaneous bleeding episodes without any obvious injury. Moderate hemophilia involves clotting factor levels between 1-5%, where bleeding typically occurs after minor trauma. Mild hemophilia is characterized by factor levels between 5-40%, and bleeding usually happens only after significant injury or surgery.

According to CDC surveillance data, the median age at diagnosis varies significantly based on severity: approximately 1 month for severe hemophilia, 8 months for moderate cases, and 36 months for mild hemophilia.

Recognizing the signs and symptoms 🔗

Early recognition of hemophilia symptoms is essential for timely diagnosis and treatment. The signs can vary depending on the severity of the condition and the child’s age.

Common bleeding manifestations 🔗

Children with hemophilia may present with prolonged bleeding after minor cuts or injuries, easy bruising that seems disproportionate to any trauma, and excessive bleeding following dental procedures or vaccinations. Many babies with severe hemophilia are first diagnosed when prolonged bleeding occurs after circumcision.

Other warning signs include frequent nosebleeds that are difficult to stop, blood in urine or stool, and in infants, unusual bleeding after a difficult delivery. Parents may also notice their child develops large bruises or lumps under the skin (hematomas) from minor bumps.

Joint bleeding: the most significant complication 🔗

Hemarthrosis, or bleeding into the joints, is the most common musculoskeletal manifestation of hemophilia, affecting 75-90% of patients with severe disease. The first joint bleed typically occurs between ages 2 and 3, most commonly affecting the knees, ankles, and elbows.

In older children, a characteristic warning sign is a tingling or bubbling sensation in the joint before pain and swelling develop. In infants and toddlers, parents might notice irritability and reluctance to use a particular limb. Symptoms of hemarthrosis include joints that feel warm, swelling, pain with movement, and reduced range of motion.

Repeated joint bleeds, if left untreated, can initiate a destructive cycle of inflammation, cartilage damage, and chronic arthropathy. This makes preventing and promptly treating joint bleeds one of the most important goals in hemophilia management.

Diagnostic approach 🔗

Diagnosing hemophilia involves a combination of family history assessment, clinical evaluation, and specific laboratory tests. When hemophilia runs in a family, testing is often performed soon after birth.

Laboratory testing 🔗

The diagnostic workup begins with screening tests that evaluate overall clotting function. A complete blood count (CBC) is performed to assess blood cell levels, though results are typically normal in hemophilia. The activated partial thromboplastin time (aPTT) measures how long it takes blood to clot and is usually prolonged in hemophilia.

The definitive diagnosis comes from clotting factor tests, also called factor assays, which determine the activity levels of factors VIII and IX. These tests not only confirm the diagnosis but also establish the type and severity of hemophilia. For newborns with a family history of hemophilia, umbilical cord blood can be tested, though factor IX levels may need to be rechecked at 6 months of age since they take time to reach normal levels.

Additionally, genetic testing can identify the specific mutation responsible for hemophilia and is particularly useful for identifying female carriers within affected families.

Treatment and management strategies 🔗

Modern treatment has transformed hemophilia from a life-threatening condition to a manageable chronic disorder. The cornerstone of treatment is replacing the missing clotting factor to restore normal blood clotting function.

Factor replacement therapy 🔗

The standard treatment for both hemophilia A and B involves intravenous infusion of clotting factor concentrates. These products are available in plasma-derived or recombinant (genetically engineered) forms. For hemophilia A, factor VIII concentrates are used, while factor IX concentrates treat hemophilia B.

Factor replacement can be administered in two ways. Episodic treatment involves giving factor concentrate after a bleed has started to stop the bleeding episode. Prophylactic treatment means regular infusions given to prevent bleeding episodes from occurring in the first place.

The importance of prophylaxis 🔗

Primary prophylaxis, which involves regular factor infusions started early in life before significant joint damage occurs, has become the gold standard of care for children with severe hemophilia. Research has consistently shown that children who receive prophylactic treatment have fewer bleeding episodes and significantly less joint damage compared to those treated only when bleeds occur.

A landmark CDC-sponsored study found that children treated prophylactically had markedly less evidence of joint damage by age 6 compared to those receiving episodic treatment. The goal of prophylaxis is to maintain clotting factor levels high enough to convert a severe phenotype into a milder one, dramatically reducing spontaneous bleeding risk.

Prophylaxis is typically initiated before age 3 years and ideally prior to the second joint bleed. For hemophilia A, the recommended dose is generally 25-40 international units per kilogram administered three times per week.

Newer treatment options 🔗

Recent advances have expanded treatment options significantly. Extended half-life factor products allow for less frequent infusions while maintaining protective factor levels. These products have longer-lasting effects in the body, improving convenience and potentially enhancing treatment adherence.

For hemophilia A, emicizumab is a non-factor therapy that mimics the function of factor VIII. Administered as a subcutaneous injection rather than intravenously, it offers a convenient alternative for prophylaxis. This medication is approved for patients with hemophilia A both with and without inhibitors.

Gene therapy represents the newest frontier in hemophilia treatment. This approach involves delivering working copies of the affected gene to enable the body to produce its own clotting factor, potentially reducing or eliminating the need for regular factor infusions.

Family education and home management 🔗

Successful hemophilia management extends far beyond medical treatments-it requires comprehensive family education and a supportive care network.

Recognizing and responding to bleeds 🔗

Parents must learn to recognize the early signs of bleeding episodes, particularly joint bleeds. Key warning signs include unusual fussiness in infants, reluctance to use a limb, joint warmth or swelling, and the characteristic tingling sensation that older children can describe. Early treatment of bleeds is crucial for preventing complications.

Families should be educated about when to seek emergency care, especially for head injuries, as intracranial bleeding is a serious complication that requires immediate treatment.

Home infusion training 🔗

Teaching families to perform factor infusions at home is a critical component of comprehensive care. Home therapy empowers families to treat bleeding episodes promptly without relying on hospital visits and enables consistent prophylactic treatment. Many treatment centers provide extensive training programs to help parents become confident in administering infusions.

Creating a safe environment 🔗

While overprotection is not recommended, reasonable safety precautions can help minimize injury risk. This includes childproofing the home, using protective gear during physical activities, and working with schools to develop appropriate safety plans. Children with hemophilia should be encouraged to participate in physical activities, as exercise promotes joint health and overall wellbeing-though contact sports may need to be avoided.

The role of comprehensive care 🔗

Hemophilia treatment centers (HTCs) provide specialized multidisciplinary care for children with bleeding disorders. These centers bring together hematologists, nurses, physical therapists, social workers, and other specialists who understand the unique needs of children with hemophilia.

Studies have shown that patients receiving care at comprehensive treatment centers have better outcomes, fewer complications, and improved quality of life compared to those treated elsewhere. HTCs also provide essential services such as genetic counseling, psychological support, and transition planning as children move into adolescence and adulthood.

What do you think? How might early diagnosis and prophylactic treatment change the long-term outlook for children with hemophilia? What challenges do you think families face when learning to manage this condition at home?

References

1. https://www.cdc.gov/hemophilia/about/index.html
2. https://www.bleeding.org/bleeding-disorders-a-z/types/hemophilia-a
3. https://www.cdc.gov/hemophilia/data-research/index.html
4. https://www.ncbi.nlm.nih.gov/books/NBK525999/
5. https://www.childrens.com/specialties-services/conditions/hemarthrosis
6. https://www.cdc.gov/hemophilia/testing/index.html
7. https://www.childrenshospital.org/conditions/hemophilia
8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2652217/
9. https://www.bleeding.org/healthcare-professionals/guidelines-on-care/masac-documents/masac-document-267-masac-recommendation-concerning-prophylaxis-for-hemophilia-a-and-b-with-and-without-inhibitors
10. https://www.hopkinsmedicine.org/health/conditions-and-diseases/hemophilia-in-children